ClinicalTrials.gg

Program

DA-5223

A development code. Also written as “DA-5223-F”, “DA-5223-M” and “DA-5223(Fasting)”.

Its studies are led by Dong-A ST.

Furthest: phase 1, since May 28, 20253 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Dong-A ST30 open or runningphase 1since May 28, 2025May 28, 2025none ahead

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. May 28, 2025First studies: 2 phase 1 studies in Healthy AdultFirst studyNCT07007533, NCT07007520
  2. Jun 1, 2026Phase 1 study in Healthy AdultNCT07633691 · 12 enrolled · South Korea

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07633691Healthy Adult · South Korea1CompletedJun 23, 202612
NCT07007533Healthy Adult · South Korea1CompletedJul 17, 202538
NCT07007520Healthy Adult · South Korea1WithdrawnNov 20250

How it is read

Names in the registry

  • “DA-5223-F”, 1 entry
  • “DA-5223-M”, 1 entry
  • “DA-5223(Fasting)”, 1 entry
  • “DA-5223(Fed)”, 1 entry
  • “DA-5223-R”, 1 entry

Codes read as this program: DA5223.

Conditions, from the studies’ own filings

    First seen by our ledger Nov 13, 2026.

    What this can’t show

    • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
    • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
    • Primary completion dates are the sponsors’ estimates and often move.
    • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.